Found: 53
Select item for more details and to access through your institution.
Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies.
- Published in:
- International Journal of Dermatology, 2010, v. 49, n. 7, p. 818, doi. 10.1111/j.1365-4632.2010.04512.x
- By:
- Publication type:
- Article
Use of pimecrolimus cream 1% (Elidel®) in the treatment of atopic dermatitis in infants and children: the effects of ethnic origin and baseline disease severity on treatment outcome.
- Published in:
- International Journal of Dermatology, 2005, v. 44, n. 1, p. 70, doi. 10.1111/j.1365-4632.2004.02234.x
- By:
- Publication type:
- Article
Pharmacokinetics, Immunogenicity, and Efficacy of Etanercept in Pediatric Patients With Moderate to Severe Plaque Psoriasis.
- Published in:
- Journal of Clinical Pharmacology, 2018, v. 58, n. 3, p. 340, doi. 10.1002/jcph.1029
- By:
- Publication type:
- Article
Outcomes of COVID-19 and Vaccination in Patients With Moderate to Severe Atopic Dermatitis Treated With Tralokinumab.
- Published in:
- JAMA Dermatology, 2022, v. 158, n. 11, p. 1327, doi. 10.1001/jamadermatol.2022.3488
- By:
- Publication type:
- Article
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: A Phase 3 Randomized Clinical Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis.
- Published in:
- Arthritis Care & Research, 2014, v. 66, n. 12, p. 1759, doi. 10.1002/acr.22404
- By:
- Publication type:
- Article
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.
- Published in:
- Archives of Dermatological Research, 2024, v. 316, n. 7, p. 1, doi. 10.1007/s00403-024-03122-w
- By:
- Publication type:
- Article
Humanized anti-CD2 monoclonal antibody treatment of plaque psoriasis: efficacy and pharmacodynamic results of two randomized, double-blind, placebo-controlled studies of intravenous and subcutaneous siplizumab.
- Published in:
- Archives of Dermatological Research, 2009, v. 301, n. 6, p. 429, doi. 10.1007/s00403-009-0961-7
- By:
- Publication type:
- Article
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Erdheim-Chester Disease of the Breast: A Case Report and Review of the Literature.
- Published in:
- Breast Journal, 2005, v. 11, n. 6, p. 462, doi. 10.1111/j.1075-122X.2005.00133.x
- By:
- Publication type:
- Article
Safety of Conventional Systemic Agents and Biologic Agents in the Treatment of Psoriasis.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2009, v. 13, p. S67, doi. 10.2310/7750.2009.00023
- By:
- Publication type:
- Article
Targeting the Interleukin-12/23 Cytokine Family in the Treatment of Psoriatic Disease.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2008, p. S1, doi. 10.2310/7750.2008/08070
- By:
- Publication type:
- Article
ISA247: Quality of Life Results from a Phase II, Randomized, Placebo-Controlled Study.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2008, v. 12, n. 6, p. 268, doi. 10.2310/7750.2008.07060
- By:
- Publication type:
- Article
Use of Anakinra (Kineret) in the Treatment of Familial Cold Autoinflammatory Syndrome with a 16-Month Foll-ow-Up.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2008, v. 12, n. 1, p. 8, doi. 10.2310/7750.2008.07050
- By:
- Publication type:
- Article
Long-Term Safety of Etanercept.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2007, v. 11, p. S23, doi. 10.2310/7750.2006.00071
- By:
- Publication type:
- Article
Long-Term Safety of Etanercept.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2007, v. 11, p. S23, doi. 10.2310/7750.2006.00071
- By:
- Publication type:
- Article
Prognostic Significance of Vascularity in Cutaneous Melanoma: Pilot Study Using In Vivo Confocal Scanning Laser Microscopy.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2006, v. 10, n. 3, p. 122, doi. 10.2310/7750.2006.00031
- By:
- Publication type:
- Article
Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2005, v. 9, p. 18, doi. 10.1007/s10227-006-0103-1
- By:
- Publication type:
- Article
Efalizumab, a reversible T-cell modulator for psoriasis.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2005, v. 9, p. 4, doi. 10.1007/s10227-006-0101-3
- By:
- Publication type:
- Article
Treatment and Management of Psoriasis with Nail Involvement: A Focus on Biologic Therapy.
- Published in:
- Dermatology (10188665), 2010, v. 221, p. 29, doi. 10.1159/000316179
- By:
- Publication type:
- Article
Quantitative HLA-G Expression in Metastasising and Non-Metastasising Primary Thin Cutaneous Melanomas.
- Published in:
- Dermatology (10188665), 2008, v. 217, n. 3, p. 281, doi. 10.1159/000150602
- By:
- Publication type:
- Article
649 - Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.028
- By:
- Publication type:
- Article
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.
- Published in:
- British Journal of Dermatology, 2024, v. 190, n. 4, p. 477, doi. 10.1093/bjd/ljad429
- By:
- Publication type:
- Article
Continuous tralokinumab treatment over 4 years in adults with moderate-to-severe atopic dermatitis provides long-term disease control.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii48, doi. 10.1093/bjd/ljad498.050
- By:
- Publication type:
- Article
Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii52, doi. 10.1093/bjd/ljad498.054
- By:
- Publication type:
- Article
Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure.
- Published in:
- British Journal of Dermatology, 2023, v. 189, n. 1, p. 42, doi. 10.1093/bjd/ljad115
- By:
- Publication type:
- Article
Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.
- Published in:
- British Journal of Dermatology, 2023, v. 188, n. 6, p. 749, doi. 10.1093/bjd/ljad035
- By:
- Publication type:
- Article
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
- Published in:
- British Journal of Dermatology, 2023, v. 188, n. 2, p. 198, doi. 10.1093/bjd/ljac040
- By:
- Publication type:
- Article
Sustained Efficacy and Safety of Pimecrolimus Cream 1% when Used Long-term (up to 26 Weeks) to Treat Children with Atopic Dermatitis.
- Published in:
- Pediatric Dermatology, 2008, v. 25, n. 3, p. 301, doi. 10.1111/j.1525-1470.2008.00671.x
- By:
- Publication type:
- Article
Mycosis Fungoides Presenting as Pigmented Purpuric Dermatitis.
- Published in:
- Pediatric Dermatology, 2006, v. 23, n. 4, p. 350, doi. 10.1111/j.1525-1470.2006.00259.x
- By:
- Publication type:
- Article
Low Systemic Absorption and Good Tolerability of Pimecrolimus, Administered as 1% Cream (Elidel®) in Infants with Atopic Dermatitis – A Multicenter, 3-Week, Open-Label Study.
- Published in:
- Pediatric Dermatology, 2005, v. 22, n. 5, p. 465, doi. 10.1111/j.1525-1470.2005.00128.x
- By:
- Publication type:
- Article
Dermacase. Can you identify this condition? Secondary syphilis.
- Published in:
- 2012
- By:
- Publication type:
- journal article
Can you identify this condition?
- Published in:
- Canadian Family Physician / Médecin de Famille Canadien, 2012, v. 58, n. 4, p. 409
- By:
- Publication type:
- Article
Secukinumab versus guselkumab in the complete resolution of ustekinumab‐resistant psoriatic plaques: The ARROW study.
- Published in:
- Experimental Dermatology, 2023, v. 32, n. 10, p. 1834, doi. 10.1111/exd.14828
- By:
- Publication type:
- Article
Safety, Efficacy, and Dosage of 1% Pimecrolimus Cream for the Treatment of Atopic Dermatitis in Daily Practice.
- Published in:
- American Journal of Clinical Dermatology, 2006, v. 7, n. 2, p. 121, doi. 10.2165/00128071-200607020-00005
- By:
- Publication type:
- Article
Topical Calcineurin Inhibitors in the Treatment of Atopic Dermatitis: A Meta-Analysis of Current Evidence.
- Published in:
- American Journal of Clinical Dermatology, 2004, v. 5, n. 4, p. 267
- By:
- Publication type:
- Article
Academic branding: erythema ab igne and use of laptop computers.
- Published in:
- 2010
- By:
- Publication type:
- Case Study
Ustekinumab and Marked Clinical Responses in Patients with Moderate to Severe Psoriasis.
- Published in:
- Psoriasis Forum, 2010, n. 1, p. 3, doi. 10.1177/247553031016a00101
- By:
- Publication type:
- Article
Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian Psoriasis Expert Panel.
- Published in:
- Journal of Cutaneous Medicine & Surgery, 2004, v. 8, n. 5, p. 321, doi. 10.1007/s10227-005-0035-1
- By:
- Publication type:
- Article
Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events: A Meta-analysis of Randomized Controlled Trials.
- Published in:
- JAMA: Journal of the American Medical Association, 2011, v. 306, n. 8, p. 864, doi. 10.1001/jama.2011.1211
- By:
- Publication type:
- Article
Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 12, p. 3031, doi. 10.1007/s13555-023-01054-3
- By:
- Publication type:
- Article
Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 3, p. 751, doi. 10.1007/s13555-022-00883-y
- By:
- Publication type:
- Article
Tralokinumab Efficacy and Safety, with or without Topical Corticosteroids, in North American Adults with Moderate-to-Severe Atopic Dermatitis: A Subanalysis of Phase 3 Trials ECZTRA 1, 2, and 3.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 11, p. 2499, doi. 10.1007/s13555-022-00805-y
- By:
- Publication type:
- Article
A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 3, p. 787, doi. 10.1007/s13555-022-00687-0
- By:
- Publication type:
- Article
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 2, p. 561, doi. 10.1007/s13555-021-00679-6
- By:
- Publication type:
- Article
Correction to: Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 61, doi. 10.1007/s13555-021-00635-4
- By:
- Publication type:
- Article
Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities.
- Published in:
- Dermatology & Therapy, 2021, v. 11, n. 2, p. 385, doi. 10.1007/s13555-021-00483-2
- By:
- Publication type:
- Article